Press Release Distribution

Members Login  |  Register  |  Why Join?   Follow us on Google+Follow us on TwitterFind us on LinkedInFind Us on FacebookSubscribe to our RSS FeedsSubscribe to our YouTube ChannelFind us on RebelMouse

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Date    |    Business Directory
All Press Releases for February 28, 2014 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version   

April trial date scheduled for transvaginal mesh MDL

MDL-2324 relating to injury from transvaginal mesh implants has been scheduled for trial in April. The MDL is currently pending in the U.S. District Court for the Southern District of West Virginia.
x-small text small text medium text large text

    February 28, 2014 /24-7PressRelease/ -- Surgical mesh has been around for decades. In the 1950s, it was solely used to repair hernias. However, in the mid 1990s, the Food and Drug Administration approved the product to treat weak pelvic floor muscles--mainly in females. Manufactures then began manufacturing transvaginal mesh.

What is transvaginal mesh?

Transvaginal mesh is essentially a synthetic surgical mesh sling. The mesh device is utilized to treat Pelvic Organ Prolapse--a condition that occurs when the pelvic muscles become too weak to support the body's internal organs. The mesh device is also used to treat Stress Urinary Incontinence, a condition in which the muscles cannot hold in urine.

Many females received the implant because both conditions typically happen as a result of child birth.


However, soon after transvaginal mesh became available and utilized on the market, hundreds of thousands of females began experiencing serious problems due to defects of the product. Along with severe pain, females experienced erosion of the vaginal epithelium, infection, and urinary problems.

Many individuals had to undergo surgical procedures, blood transfusions and abscess draining to correct the problems that stemmed from the defective mesh device.

As a result, hundreds of thousands of civil lawsuits were filed all across the country against the various manufacturers of the product including Endo Pharmaceuticals, Inc., Ethicon (a Johnson & Johnson subsidiary), Boston Scientific, and C.R. Bard, among others.

Cases consolidated

However, due to the common question of fact among all situations, the cases were consolidated under what's referred to as multidistrict litigation, or MDL. In MDL, cases are combined and transferred under one jurisdiction with one judge. When so many similar cases are involved, MDL helps to speed up the process and decrease the strain on the court system.

Presently, there are six different MDL consolidations with roughly 40,000 individual transvaginal mesh cases pending across the U.S.

Trial scheduled for MDL-2324

According to the latest reports, MDL-2324 pending in the U.S. District Court for the Southern District of West Virginia has been scheduled for trial with Judge Joseph R. Goodwin presiding. The defendants include American Medical Systems, Inc. (an Endo Pharmaceutical company) and five other transvaginal mesh device manufacturers.

The first trial is expected to begin April 7, 2014.

Hope for victims

The consolidated cases, however, are likely to settle. Last year, Endo Pharmaceutical, Inc. paid out a $54.5 million dollar settlement to compensate victims injured by the mesh implant.

Bloomberg, an online source for business, economic and financial information, estimates that there are roughly 13,500 state and federal lawsuits currently pending against American Medical Systems.

Article provided by Tooher Wocl & Leydon LLC
Visit us at

Press release service and press release distribution provided by

# # #

Read more Press Releases from FL Web Advantage:

Contact Information:
FL Web Advantage

E-Mail: Email us Here
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7PressRelease. We are unable to assist you with any information regarding this release. 24-7PressRelease disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.